Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAFV600E–mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary ana...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Tabernero, Josep, Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona, Wasan, Harpreet, Yoshino, Takayuki, Desai, Jayesh, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod Kyrre, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Elez, Elena, Gollerkeri, Ashwin, Maharry, Kati, Christy-Bittel, Janna, Kopetz, Scott
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2021
Soggetti:
RAPID COMMUNICATIONS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078423/
https://ncbi.nlm.nih.gov/pubmed/33503393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02088
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi